Abstract
C1q nephropathy is a rare idiopathic glomerulopathy characterized by mesangial deposition of immunoglobulin and complement with C1q dominance or co-dominance, and the absence of clinical and laboratory evidence of systemic lupus erythematosus. Its clinical course is unpredictable and the response to corticosteroid or cytotoxic treatment is variable. Here, we report two cases of C1q nephropathy, one in a child and one in an adult, both presenting with impaired renal function and massive proteinuria. Both patients failed to respond to immunosuppressive medications; however, rituximab, an anti-CD20 antibody, was effective in preserving renal function in one patient and eliminating the need for hemodialysis in the other. In one patient, histologic regression of abnormalities was documented over 3 years post-treatment. Both patients have remained off other immunosuppressive medication for a prolonged period with stable renal function. These cases are, to our knowledge, the first reported successful treatment of C1q nephropathy with rituximab.
Similar content being viewed by others
References
Mii A, Shimizu A, Masuda Y, Fujita E, Aki K, Ishizaki M, et al. Current status and issues of C1q nephropathy. Clin Exp Nephrol. 2009;13:263–74.
Lau KK, Gaber LW, Delos Santos NM, Wyatt RJ. C1q nephropathy: features at presentation and outcome. Pediatr Nephrol. 2005;20:744–9.
Markowitz GS, Schwimmer JA, Stokes MB, Nasr S, Seigle RL, Valeri AM, et al. C1q nephropathy: a variant of focal segmental glomerulosclerosis. Kidney Int. 2003;64:1232–40.
Ahmed MS, Wong CF. Rituximab and nephrotic syndrome: a new therapeutic hope? Nephrol Dial Transpl. 2008;23:11–7.
Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and mycophenolate mofetil (MMF)-resistant minimal change nephrotic syndrome after rituximab therapy. Nephrol Dial Transpl. 2008;23:377–80.
Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52:501–13.
Bitzan M, Ouahed JD, Krishnamoorthy P, Bernard C. Rituximab treatment of collapsing C1q glomerulopathy: clinical and histopathological evolution. Pediatr Nephrol. 2008;23:1355–61.
Jennette JC, Hipp CG. C1q nephropathy: a distinct pathologic entity usually causing nephrotic syndrome. Am J Kidney Dis. 1985;6:103–10.
Iskandar SS, Browning MC, Lorentz WB. C1q nephropathy: a pediatric clinicopathologic study. Am J Kidney Dis. 1991;18:459–65.
Vizjak A, Ferluga D, Rozic M, Hvala A, Lindic J, Levart TK, et al. Pathology, clinical presentations, and outcomes of C1q nephropathy. J Am Soc Nephrol. 2008;19:2237–44.
Hisano S, Fukuma Y, Segawa Y, Niimi K, Kaku Y, Hatae K, et al. Clinicopathologic correlation and outcome of C1q nephropathy. Clin J Am Soc Nephrol. 2008;3:1637–43.
Marcus R, Hagenbeek A. The therapeutic use of rituximab in non-Hodgkin’s lymphoma. Eur J Haematol Suppl. 2007;67:5–14.
Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid dependent minimal change nephrotic syndrome. Pediatr Nephrol. 2006;21:1698–700.
Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-resistant nephrotic syndrome. N Engl J Med. 2007;356:2751–2.
Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med. 2006;354:1961–3.
Fernandez-Fresnedo G, Segarra A, González E, Alexandru S, Delgado R, Ramos N, et al. Trabajo de Enfermedades Glomerulares de la Sociedad Española de Nefrología (GLOSEN): rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2009;4:1317–23.
Segarra A, Praga M, Ramos N, Polanco N, Cargol I, Gutierrez-Solis E, et al. Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. Clin J Am Soc Nephrol. 2009;4:1083–8.
Berger SP, Roos A, Daha MR. Complement and the kidney: what the nephrologists needs to know in 2006? Nephrol Dial Transpl. 2005;20:2613–9.
Soares MP, Bach FH. C1q receptors and endothelial cell activation. J Lab Clin Med. 1999;133:520–2.
Uwatoko S, Aotsuka S, Okawa M, Egusa Y, Yokohari R, Aizawa C, et al. Characterization of C1q-binding IgG complexes in systemic lupus erythematosus. Clin Immunol Immunopathol. 1984;30:104–16.
Hauptrock B, Hess G. Rituximab in the treatment of non-Hodgkin’s lymphoma. Biologics. 2008;4:619–33.
Acknowledgments
We would like to acknowledge the support of the International Society of Nephrology through its Renal Sister Center Program (All India Institute of Nephrology and Cedars-Sinai Medical Center).
Conflict of interest
Stanley C. Jordan, M.D. has a research grant from Genentech®, the manufacturer of rituximab to study its effects in kidney transplant patients. This grant did not conflict with this report. No other authors have disclosures to make regarding conflict of interest.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sinha, A., Nast, C.C., Hristea, I. et al. Resolution of clinical and pathologic features of C1q nephropathy after rituximab therapy. Clin Exp Nephrol 15, 164–170 (2011). https://doi.org/10.1007/s10157-010-0377-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-010-0377-x